172@29@17@243!~!172@29@0@53!~!|news|tags|dr-reddys.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
you are here: HomeNewsDr reddys
dr reddys
Jump to
226 Results Found
  • Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial Sep 08, 2020 01:30 PM IST

    Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial

    Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated September 07, 2020.

  • Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial Aug 04, 2020 05:01 PM IST

    Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial

    Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated July 29, 2020.

  • Dr Reddy’s investment case bolstered by improved margins and product launch guidance Jul 30, 2020 09:19 AM IST

    Dr Reddy’s investment case bolstered by improved margins and product launch guidance

    Key drag for the Dr Reddy's is India business. Compared to its peers, it has a low revenue share in India and that too is majorly in the acute category

  • Dr Reddy’s: Primed by strong bets on complex pharma opportunities, good for risk takers May 21, 2020 08:13 AM IST

    Dr Reddy’s: Primed by strong bets on complex pharma opportunities, good for risk takers

  • Working on products related to COVID-19: Dr Reddy's May 20, 2020 08:18 PM IST

    Working on products related to COVID-19: Dr Reddy's

    GV Prasad, Co-Chairman and MD of Dr Reddy's, said the company is working with partners on these drugs but did not divulge details.

  • Will the Wockhardt move help Dr Reddy's break into the big league? Feb 14, 2020 07:19 PM IST

    Will the Wockhardt move help Dr Reddy's break into the big league?

    Analysts say unlike previous attempts, Dr Reddy’s is making more concerted effort to expand in India

  • Emerging markets like India will gain capital allocation: Dr Reddy’s GV Prasad Feb 13, 2020 11:36 AM IST

    Emerging markets like India will gain capital allocation: Dr Reddy’s GV Prasad

    Dr Reddy's Laboratories sprung a surprise on Wednesday when it announced that it will acquire the domestic business of Wockhardt Pharma for Rs 1,850 crore

  • Deleveraging and deals – a healthy prescription for pharma sector Jan 29, 2020 09:22 AM IST

    Deleveraging and deals – a healthy prescription for pharma sector

    A stronger domestic market foundation helps as a buffer from fluctuating US sales.

  • Don’t miss! Stocks from life insurance and AMC likely to be included in Sensex & Nifty Nov 21, 2019 11:49 AM IST

    Don’t miss! Stocks from life insurance and AMC likely to be included in Sensex & Nifty

    We find large Insurance companies being part of most global Indices, so we also should traverse a similar path and see two or three insurance companies being part of Sensex or the Nifty in the future, says Rusmik Oza of Kotak Securities.

  • Exclusive | Cipla, Dr Reddy's, Carlyle and Hong Kong fund in fray for Wockhardt divisions Nov 15, 2019 04:57 PM IST

    Exclusive | Cipla, Dr Reddy's, Carlyle and Hong Kong fund in fray for Wockhardt divisions

    Wockhardt has a diversified product portfolio with presence in therapeutic segments such as cardiology, dermatology, diabetes, respiratory and ophthalmology. It is not clear which of these divisions will be sold.

  • Dr Reddy's Chinese gamble -- build biz on early mover advantage, recent tender wins Nov 04, 2019 07:17 PM IST

    Dr Reddy's Chinese gamble -- build biz on early mover advantage, recent tender wins

    Dr Reddy’s is the first Indian company and the second international drug company after Sandoz to be selected and win a supply tender in China under the Quality Consistency Evaluation (QCE) system.

  • Ranitidine recall impacts Dr Reddy's P&L by Rs 40 crore Nov 04, 2019 06:20 PM IST

    Ranitidine recall impacts Dr Reddy's P&L by Rs 40 crore

    The city-based drug maker in a filing with bourses had said the recall which began on October 1, is at the retail level for over-the-counter (OTC) products and at the consumer level for prescription products of all of its Ranitidine medications sold in the US due to confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by FDA.

  • Dr Reddy's gets 4 observations from USFDA for Srikakulam plant Oct 26, 2019 07:47 PM IST

    Dr Reddy's gets 4 observations from USFDA for Srikakulam plant

    The audit of the company's API Srikakulam Plant (SEZ) by the United States Food and Drug Administration (USFDA) was completed on Friday, the Hyderabad-based pharma major said in a regulatory filing.

  • Dr Reddy's recalls all its ranitidine products in US Oct 23, 2019 02:13 PM IST

    Dr Reddy's recalls all its ranitidine products in US

    The city-based drug maker said in a filing with bourses that the recall, which began on October 1, is at the retail level for Over-The-Counter products and at the consumer level for prescription products of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by FDA.

  • Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay Oct 14, 2019 03:56 PM IST

    Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay

    Net Sales are expected to increase by 9.7 percent Y-o-Y (up 8.4 percent Q-o-Q) to Rs. 4,167.1 crore, according to Emkay.

  • Mitsubishi UFJ Financial Group raises stake in Dr Reddy's to 8.41% Aug 06, 2019 08:01 PM IST

    Mitsubishi UFJ Financial Group raises stake in Dr Reddy's to 8.41%

    Before the acquisition, MUFG held 0.05 percent stake in Dr Reddy's.

  • Dr Reddy's Q1 result: Net profit rises 45% YoY to Rs 662.8cr led by one-off gain Jul 29, 2019 04:40 PM IST

    Dr Reddy's Q1 result: Net profit rises 45% YoY to Rs 662.8cr led by one-off gain

    The net profit increase is due to a one-off receipt of Rs 350 crore from Celgene, pursuant to settlement agreement related to Revlimid brand capsules in Canada.

  • Dr Reddy launches generic version of Allegra D in US Jul 19, 2019 11:57 AM IST

    Dr Reddy launches generic version of Allegra D in US

    Allegra-D 12 HR is a trademark of Aventisub II Inc.

  • Tepid performance of Dr Reddy's specialty biz shows segment not yet ripe Jun 24, 2019 07:56 PM IST

    Tepid performance of Dr Reddy's specialty biz shows segment not yet ripe

    Other Indian drug companies such as Sun Pharma and Lupin, who ventured into specialty business, are also facing challenges in scaling their products.

  • Dr Reddy's launches therapeutic equivalent of Vitamin K1 in US Jun 22, 2019 07:45 PM IST

    Dr Reddy's launches therapeutic equivalent of Vitamin K1 in US

    "We're pleased to bring this product to market for the customers and patients who will benefit from access to this medicine and who have in the past experienced supply disruptions in the market place," said Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories.

  • Dr Reddy's renews efforts to push India biz amid US pricing pressure Jun 06, 2019 09:41 PM IST

    Dr Reddy's renews efforts to push India biz amid US pricing pressure

    Indian business constituted about 16 percent of Dr Reddy’s Rs 15,385 crore revenues in FY19 compared to North America’s 39 percent.

  • Dr Reddy's to launch 20 products in US in FY20 May 17, 2019 10:23 PM IST

    Dr Reddy's to launch 20 products in US in FY20

    The company anticipates US FDA approval for generic Nuvaring in the first half of FY20, while the launch of generic Copaxone in the US may get further delayed as the company received additional queries from the drug regulator relating to the product, the management said.

  • Indian pharma majors deny allegations of price fixing in US May 14, 2019 10:15 PM IST

    Indian pharma majors deny allegations of price fixing in US

    The companies have been accused of violating antitrust laws by fixing prices and allocating customers.

  • Dr Reddy's sells specialty derma brands in US to Encore Dermatology Apr 02, 2019 11:34 AM IST

    Dr Reddy's sells specialty derma brands in US to Encore Dermatology

    Sernivo Spray, Promiseb topical Cream and Trainex are the brands sold to US-based Encore Dermatology.

  • Dr Reddy's may seek over $70m in compensation from Indivior for lost profit on generic Suboxone Mar 12, 2019 01:54 PM IST

    Dr Reddy's may seek over $70m in compensation from Indivior for lost profit on generic Suboxone

    Indivior, a spin-off of British drug maker Reckitt Benckiser, had managed to block sales of Dr Reddy’s generic version of Suboxone Film through a court injunction since July on grounds of pending patent litigation

Sections